peterson_600

Sandra Peterson joins J&J’s executive committee

pharmafile | September 20, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing J&J, JJ, Sandra Peterson 

Sandra Peterson will join Johnson & Johnson on 1 December as Group Worldwide chairman and member of the company’s executive committee.

She will have responsibility for the Consumer Group of Companies, Information Technology, and Global Supply Chain.

Currently the chairman and chief executive of Bayer CropScience AG, based in Europe, Peterson has experience in pharmaceuticals, medical devices, consumer goods, healthcare intermediaries and strategy development.

“Sandi Peterson is an experienced global leader known for her strategic thinking and proven track record in growing businesses,” said Alex Gorsky, chief executive.

Advertisement

“She brings 25 years of experience to her new role, which will draw on her expertise in building fully integrated global businesses, and focusing on growth.”

Peterson has held her current role at Bayer since 2010. Previously, she was president and chief executive officer of Bayer Medical Care and president of Bayer HealthCare AG’s Diabetes Care Division.

Prior to joining Bayer in 2005, Peterson spent five years in leadership roles at Medco Health Solutions. She previously led global research and development, procurement and regulatory affairs at Nabisco, and in strategy, finance and product development at Whirlpool Corporation.

Related Content

J&J seek approval for first drug to treat high-risk smoldering myeloma

Earlier in November, Johnson & Johnson innovative medicine have applied to the US Food and …

lungs

European Commission approves combination chemotherapy for treatment of advanced EGFR-mutated non-small cell lung cancer in adult patients

Today, Janssen-Cilag International, part of Johnson & Johnson (J&J) has announced that the European Comission …

J&J seeks FDA approval of Spravato as monotherapy for treatment-resistant depression

Johnson & Johnson (J&J) has announced that it has submitted a supplemental New Drug Application …

The Gateway to Local Adoption Series

Latest content